Effects of an Antifibrin Monoclonal Antibody and Fragments thereof on Some Properties of Fibrin

Summary

Antifibrin monoclonal antibody Y22, of IgG₁-subclass, has its epitope in the D-domain of fibrin. In a thrombin time assay, Y22 and its F(ab)₂ fragments interfere with clotting of citrated plasma. Transmission and scanning electronmicroscopic studies show that clotting of citrated blood or plasma in the presence of Y22 results in formation of thin, short fibrin fibres. The (smaller) Fab fragments of Y22 did not have an anti-clotting effect. This suggests that the anticoagulant effect of Y22 is due to steric hindrance of the association of fibrin monomers. A control antibody and its F(ab)₂ and Fab fragments have no effect on fibrin formation.

In a parabolic rate assay, Y22 Fab fragments interfered strongly with the fibrin-induced enhancement of the t-PA-catalyzed plasminogen activation, whereas intact Y22 and a control antibody did not. In contrast with their effects on the fibrin assembly, the effects of Y22, Y22-F(ab)₂ and Y22-Fab on the capacity of fibrin to act as a rate-enhancer in the plasminogen activation by t-PA appears to decrease with the size of the immunoreactive entity. As is discussed, this may be due to the differential accessibility of sites involved in stimulation and polymerization which are located in the fibrin D-domain.

Keywords

Fibrin - Monoclonal antibodies

• References

• 1 Blombäck B. Studies on the action of thrombotic enzymes on bovine fibrinogen as measured by N-terminal analysis. Ark Kemi 1958; 12: 321-335
• 2 Hantgan RR, Hermans J. Assembly of fibrin: a light scattering study. J Biol Chem 1979; 254: 11272-11281
• 3 Shen LL, Hermans J, McDonagh J, McDonagh RP. Role of fibrinopeptide B release: comparison of fibrins produced by thrombin and ancrod. Am J Physiol 1977; 232: 629-633
• 4 Feitsma RI J, Blok D, Wasser M NJ M, Nieuwenhuizen W, Pauwels EK J. A new method for ^99mTc-labelling of protein with an application to clot detection with an antifibrin monoclonal antibody. Nucl Med Commun 1987; 8: 771-7
• 5 Haverkate F, Timan G, Nieuwenhuizen W. Anticlotting properties of fragments D from human fibrinogen and fibrin. Eur J Clin Invest 1979; 9: 253-255
• 6 Voskuilen M, Vermond A, Veeneman GH, Van Boom JH, Klasen EA, Zegers ND, Nieuwenhuizen W. Fibrinogen lysine residue Aα 157 plays a crucial role in the fibrin-induced acceleration of plasminogen activation catalyzed by tissue-type plasminogen activator. J Biol Chem 1987; 262: 5944-5946
• 7 Van Ruijven-Vermeer IA M, Nieuwenhuizen W. Purification of rat fibrinogen and its constituent chains. Biochem J 1978; 169: 653-658
• 8 Haverkate F, Timan G. Preparation of highly purified bovine fibrin plates. In: Davidson JF, Samama MM, Desnoyers PC. (eds.) Progress in Chemical Fibrinolysis and Thrombolysis, Vol. 2. Raven Press; New York: 1976. pp 67-71
• 9 Wasser M NJ M, Koppert PW, Arndt JW, Emeis JJ, Feitsma RI J, Pauwels EK J, Nieuwenhuizen W. An antifibrin monoclonal antibody, useful in immunoscintigraphic detection of thrombi. Blood 1989; 74: 708-714
• 10 Parham P, Androlewicz MJ, Brodsky FM, Holmes NJ, Ways JP. Monoclonal antibodies: purification, fragmentation and application to structural and functional studies of class I MHC antigens. J Immunol Methods 1982; 53: 133-173
• 11 Bos ES, Van der Doelen AA, Van Rooy N, Schuurs A HW M. 3,3′,5,5′-Tetramethylbenzidine as an Ames negative chromogen for horseradish peroxidase in enzyme immunoassay. J Immunoassay 1981; 2: 187-204
• 12 Verheijen JH, Nieuwenhuizen W, Wijngaards G. Activation of plasminogen by tissue activator is increased specifically in the presence of certain soluble fibrin(ogen) fragments. Thromb Res 1982; 27: 377-385
• 13 Suenson E, Peterson LC. Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator. Biochim Biophys Acta 1986; 870: 510-519